195 related articles for article (PubMed ID: 31639245)
1. Psoriasis and pregnancy in the biologic era, a feared scenario. What do we do now?
Tirelli LL; Luna PC; Cristina E; Larralde M
Dermatol Ther; 2019 Nov; 32(6):e13137. PubMed ID: 31639245
[TBL] [Abstract][Full Text] [Related]
2. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
Gottlieb AB; Blauvelt A; Thaçi D; Leonardi CL; Poulin Y; Drew J; Peterson L; Arendt C; Burge D; Reich K
J Am Acad Dermatol; 2018 Aug; 79(2):302-314.e6. PubMed ID: 29660421
[TBL] [Abstract][Full Text] [Related]
3. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
Lebwohl M; Blauvelt A; Paul C; Sofen H; Węgłowska J; Piguet V; Burge D; Rolleri R; Drew J; Peterson L; Augustin M
J Am Acad Dermatol; 2018 Aug; 79(2):266-276.e5. PubMed ID: 29660425
[TBL] [Abstract][Full Text] [Related]
4. Certolizumab Pegol in Plaque Psoriasis: Considerations for Pregnancy.
Strain J; Leis M; Lee KO; Fleming P
Skin Therapy Lett; 2021 Mar; 26(2):1-5. PubMed ID: 33769772
[TBL] [Abstract][Full Text] [Related]
5. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.
Blauvelt A; Reich K; Lebwohl M; Burge D; Arendt C; Peterson L; Drew J; Rolleri R; Gottlieb AB
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):546-552. PubMed ID: 30242918
[TBL] [Abstract][Full Text] [Related]
6. A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data.
Kolli SS; Kepley AL; Cline A; Feldman SR
Expert Opin Drug Saf; 2019 Jun; 18(6):523-536. PubMed ID: 31046481
[TBL] [Abstract][Full Text] [Related]
7. The use of biologic agents in pregnancy and breastfeeding.
Horst S; Kane S
Gastroenterol Clin North Am; 2014 Sep; 43(3):495-508. PubMed ID: 25110255
[TBL] [Abstract][Full Text] [Related]
8. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration.
Rademaker M; Agnew K; Andrews M; Armour K; Baker C; Foley P; Frew J; Gebauer K; Gupta M; Kennedy D; Marshman G; Sullivan J
Australas J Dermatol; 2018 May; 59(2):86-100. PubMed ID: 28543445
[TBL] [Abstract][Full Text] [Related]
9. Le choix thérapeutique : médicaments du psoriasis et grossesse avant, pendant et après la grossesse.
Villani AP
Eur J Dermatol; 2020 Oct; 30(S1):8-13. PubMed ID: 33242008
[TBL] [Abstract][Full Text] [Related]
10. Psoriasis in pregnancy: a review (II).
Ruiz V; Manubens E; Puig L
Actas Dermosifiliogr; 2014 Nov; 105(9):813-21. PubMed ID: 24314892
[TBL] [Abstract][Full Text] [Related]
11. Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kimball AB; Guenther L; Kalia S; de Jong EMGJ; Lafferty KP; Chen DY; Langholff W; Shear NH
JAMA Dermatol; 2021 Mar; 157(3):301-306. PubMed ID: 33533924
[TBL] [Abstract][Full Text] [Related]
12. Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding.
Kurizky PS; Ferreira Cde C; Nogueira LS; Mota LM
An Bras Dermatol; 2015; 90(3):367-75. PubMed ID: 26131868
[TBL] [Abstract][Full Text] [Related]
13. Psoriatic alopecia-like paradoxical reaction to certolizumab pegol.
Aragón-Miguel R; Calleja-Algarra A; Vico-Alonso C; Sánchez-Velázquez A; Garrido MC; Ortiz-Romero PL; Rivera-Díaz R
Int J Dermatol; 2019 Jun; 58(6):e118-e120. PubMed ID: 30825196
[No Abstract] [Full Text] [Related]
14. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series.
Lund T; Thomsen SF
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28071837
[TBL] [Abstract][Full Text] [Related]
15. Certolizumab pegol for the treatment of psoriasis.
Campanati A; Benfaremo D; Luchetti MM; Ganzetti G; Gabrielli A; Offidani A
Expert Opin Biol Ther; 2017 Mar; 17(3):387-394. PubMed ID: 28165828
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
[TBL] [Abstract][Full Text] [Related]
17. Lactation and the use of biologic immunosuppressive medications.
Witzel SJ
Breastfeed Med; 2014 Dec; 9(10):543-6. PubMed ID: 25347779
[TBL] [Abstract][Full Text] [Related]
18. Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian Experience.
Bardazzi F; Magnano M; Campanati A; Loconsole F; Carpentieri A; Potenza C; Bernardini N; Di Lernia V; Carrera C; Raone B; Patrizi A; Loi C
Acta Derm Venereol; 2017 Aug; 97(8):989-990. PubMed ID: 28512671
[No Abstract] [Full Text] [Related]
19. Elderly psoriatic patients under biological therapies: an Italian experience.
Ricceri F; Bardazzi F; Chiricozzi A; Dapavo P; Ferrara F; Mugheddu C; Romanelli M; Rongioletti F; Prignano F
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):143-146. PubMed ID: 29906311
[TBL] [Abstract][Full Text] [Related]
20. Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors.
Campanati A; Molinelli E; Brisigotti V; Offidani A
Curr Pharm Biotechnol; 2017; 18(12):945-963. PubMed ID: 29424306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
